atorvastatin has been researched along with Dengue in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganesh, K; Kumar, A; Manoj, H; Murugasamy, V; Muthukumaravel, S; Niranjan, R; Sankari, T; Sunilkumar, A; Vidhyapriya, P | 1 |
| Cordero-Rivera, CD; De Jesús-González, LA; Del Ángel, RM; Farfan-Morales, CN; Hurtado-Monzón, AM; Jiménez-Camacho, R; Meraz-Ríos, MA; Osuna-Ramos, JF; Palacios-Rápalo, SN; Reyes-Ruiz, JM | 1 |
2 other study(ies) available for atorvastatin and Dengue
| Article | Year |
|---|---|
Atorvastatin attenuates NS1 (Non-structural protein-1) of dengue type-2 serotype-induced expressions of matrix metalloproteinases in HL-60 cells, differentiated to neutrophils: Implications for the immunopathogenesis of dengue viral disease.
Topics: Antibodies, Viral; Atorvastatin; Dengue; Dengue Virus; HL-60 Cells; Humans; Interleukin-13; Interleukin-6; Matrix Metalloproteinase 1; Matrix Metalloproteinase 13; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Neutrophils; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Viral Nonstructural Proteins | 2022 |
Cholesterol-Lowering Drugs as Potential Antivirals: A Repurposing Approach against Flavivirus Infections.
Topics: Animals; Antiviral Agents; Atorvastatin; Cholesterol; Dengue; Dengue Virus; Drug Repositioning; Ezetimibe; Flavivirus; Flavivirus Infections; Mice; Zika Virus; Zika Virus Infection | 2023 |